

Andrew A Somogyi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9469253/andrew-a-somogyi-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176
papers

6,815
citations

46
h-index

76
g-index

184
ext. papers

7,607
ext. citations

4.8
avg, IF

5.58
L-index

#	Paper	IF	Citations
176	New pharmacological perspectives and therapeutic options for opioids: Differences matter.. <i>Anaesthesia and Intensive Care</i> , 2022 , 310057X211063891	1.1	1
175	Toll-Like Receptors change morphine-induced antinociception, tolerance and dependence: studies using male and female TLR and Signalling gene KO mice.. <i>Brain, Behavior, and Immunity</i> , 2022 ,	16.6	1
174	A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022 , 48674221083868	2.6	0
173	The effect of acute morphine on sleep in male patients suffering from sleep apnea: Is there a genetic effect? An RCT Study. <i>Journal of Sleep Research</i> , 2021 , 30, e13249	5.8	0
172	PharmVar GeneFocus: CYP2B6. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 82-97	6.1	7
171	Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3901-3909	3.8	3
170	Innate Immune and Neuronal Genetic Markers Are Highly Predictive of Postoperative Pain and Morphine Patient-Controlled Analgesia Requirements in Indian but Not Chinese or Malay Hysterectomy Patients. <i>Pain Medicine</i> , 2021 , 22, 2648-2660	2.8	1
169	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 302-309	6.1	48
168	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 888-896	6.1	55
167	Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. <i>Clinical and Translational Science</i> , 2021 , 14, 2521-2531	4.9	2
166	Instability of Efavirenz Metabolites Identified During Method Development and Validation. <i>Journal of Pharmaceutical Sciences</i> , 2021 , 110, 3362-3366	3.9	1
165	Pharmacogenetics of statin intolerance. <i>Internal Medicine Journal</i> , 2020 , 50, 506-507	1.6	3
164	Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. <i>Pain Medicine</i> , 2020 , 21, 2007-2008	2.8	1
163	Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1015-1020	3.8	4
162	High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2163-2169	3.8	10
161	The Prevalence, Impact, and Risk Factors for Persistent Pain After Breast Cancer Surgery in a New Zealand Population. <i>Pain Medicine</i> , 2019 , 20, 1803-1814	2.8	4
160	No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1686	5.6	1

159	Effects of Electroacupuncture on Opioid Consumption in Patients with Chronic Musculoskeletal Pain: A Multicenter Randomized Controlled Trial. <i>Pain Medicine</i> , 2019 , 20, 397-410	2.8	19
158	A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression - the way to go? Results from a pilot randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2019 , 33, 260-261	4.6	
157	Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 528-532	3.2	4
156	Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. <i>Pharmacogenetics and Genomics</i> , 2019 , 29, 9-17	1.9	5
155	The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial. <i>Thorax</i> , 2019 , 74, 177-184	7.3	18
154	Conference report: pharmacogenomics in special populations at WCP2018. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 467-475	3.8	3
153	Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. <i>Pain Medicine</i> , 2019 , 20, 119-128	2.8	20
152	CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018 , 123, 320-326	3.1	15
151	Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2018 , 32, 397-407	4.6	42
150	Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2433-2442	3.8	7
149	Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats. <i>Pharmacology Research and Perspectives</i> , 2018 , 6, e00406	3.1	1
148	Pharmacogenomics in the Oceania region: Precision medicine challenges. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, SY48-1	0	
147	Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 153-164	1.9	6
146	Comments on Cooper et al.'s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 489	3.8	2
145	Impaired psychomotor function and plasma methadone and levo-alpha-acetylmethadol (LAAM) concentrations in opioid-substitution patients. <i>Experimental and Clinical Psychopharmacology</i> , 2017 , 25, 223-233	3.2	
144	Advances in drug metabolism and pharmacogenetics research in Australia. <i>Pharmacological Research</i> , 2017 , 116, 7-19	10.2	8
143	Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial. <i>Comprehensive Psychiatry</i> , 2017 , 73, 31-34	7.3	4
142	CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 977-985	6.2	8

141	Genomic testing as a tool to optimise drug therapy. <i>Australian Prescriber</i> , 2017 , 40, 101-104	1.4	8
140	A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol. <i>BMJ Open</i> , 2017 , 7, e018100	3	16
139	Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. <i>Pain</i> , 2016 , 157, 2458-2466	8	17
138	Clinically Significant Interactions with Anti-addiction Agents 2016 , 565-577		
137	Editors' Report for 2015, December 2015. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 6-7	3.8	78
136	Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. <i>Xenobiotica</i> , 2016 , 46, 278-87	2	11
135	Editors' report for 2014, November 2014. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 4-5	3.8	78
134	Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors?. <i>BMJ Open</i> , 2015 , 5, e006818	3	19
133	Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats. <i>Xenobiotica</i> , 2015 , 45, 3-9	2	3
132	CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 276-84	3.8	39
131	Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl. <i>PLoS ONE</i> , 2015 , 10, e0137179	3.7	12
130	Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling. <i>Brain, Behavior, and Immunity</i> , 2015 , 45, 245-52	16.6	18
129	Pharmacogenetics of opioid response. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 97, 125-7	6.1	27
128	Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 185-94	1.9	37
127	Pharmacogenomics of methadone maintenance treatment. <i>Pharmacogenomics</i> , 2014 , 15, 1007-27	2.6	33
126	Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. <i>World Journal of Biological Psychiatry</i> , 2014 , 15, 579-84	3.8	53
125	Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. <i>BMC Anesthesiology</i> , 2014 , 14, 33	2.4	5
124	Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014 , 945-946, 171-7	3.2	16

123	Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report. <i>Biological Psychiatry</i> , 2014 , 76, e1-2	7.9	25
122	Editors' pick 2013. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 228-32	3.8	
121	Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia. <i>Journal of Molecular Neuroscience</i> , 2014 , 52, 497-506	3.3	13
120	The effects of a single mild dose of morphine on chemoreflexes and breathing in obstructive sleep apnea. <i>Respiratory Physiology and Neurobiology</i> , 2013 , 185, 526-32	2.8	38
119	The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 1264-72	4	35
118	Editors' Report, 2012. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 301-302	3.8	78
117	The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 208-16	3.8	25
116	Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013 , 47, 710-27	2.6	80
115	Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 617-23	3.2	24
114	Does Intraoperative Ketamine Attenuate Inflammatory Reactivity Following Surgery? A Systematic Review and Meta-Analysis. <i>Survey of Anesthesiology</i> , 2013 , 57, 90-91		
113	Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 786-94	3.8	19
112	Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 835-41	3.8	18
111	Drugs against Acute and Chronic Pain 2012 , 403-428		2
110	ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. <i>Pharmacogenomics and Personalized Medicine</i> , 2012 , 5, 53-62	2.1	29
109	Morphine activates neuroinflammation in a manner parallel to endotoxin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 6325-30	11.5	311
108	Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. <i>British Journal of Pharmacology</i> , 2012 , 165, 1319-29	8.6	64
107	Editors' pick 2011. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 4-8	3.8	0
106	Editors' report, November 2011. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 159-160	3.8	78

105	The effect of methadone on emotional reactivity. <i>Addiction</i> , 2012 , 107, 388-92	4.6	13
104	Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis. <i>Anesthesia and Analgesia</i> , 2012 , 115, 934-43	3.9	125
103	Adoptive transfer of peripheral immune cells potentiates allodynia in a graded chronic constriction injury model of neuropathic pain. <i>Brain, Behavior, and Immunity</i> , 2011 , 25, 503-13	16.6	21
102	Naloxone-precipitated morphine withdrawal behavior and brain IL-1 β expression: comparison of different mouse strains. <i>Brain, Behavior, and Immunity</i> , 2011 , 25, 1223-32	16.6	47
101	Editors' pick 2010. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 3-6	3.8	
100	Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 688-93	3.2	13
99	Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy,. <i>Blood</i> , 2011 , 118, 3501-3501	2.2	
98	(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. <i>British Journal of Clinical Pharmacology</i> , 2010 , 70, 895-902	3.8	19
97	In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010 , 334, 609-18	4.7	68
96	A novel animal model of graded neuropathic pain: utility to investigate mechanisms of population heterogeneity. <i>Journal of Neuroscience Methods</i> , 2010 , 193, 47-53	3	35
95	Pharmacogenetics in Palliative Care 2010 , 115-125		
94	Role of active metabolites in the use of opioids. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 121-39	2.8	83
93	Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 1113-20	2.8	14
92	Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. <i>OMICS A Journal of Integrative Biology</i> , 2009 , 13, 43-61	3.8	45
91	Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. <i>Journal of Pain</i> , 2009 , 10, 316-22	5.2	122
90	Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 869-76	1.9	35
89	The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio. <i>Experimental and Clinical Psychopharmacology</i> , 2009 , 17, 146-53	3.2	8
88	Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. <i>Pharmacogenomics and Personalized Medicine</i> , 2009 , 2, 9-19	2.1	15

87	Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 347-54	3.8	5
86	Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 640-7	3.8	16
85	Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. <i>Brain, Behavior, and Immunity</i> , 2008 , 22, 1178-89	16.6	237
84	Antinociceptive effects of high-dose remifentanyl in male methadone-maintained patients. <i>European Journal of Pain</i> , 2008 , 12, 926-33	3.7	13
83	Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 562-71	4.1	40
82	Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 777-85	6.2	56
81	Pharmacogenetics of opioids. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 429-44	6.1	262
80	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 128-38	4	20
79	Cerebral kinetics of oxycodone in conscious sheep. <i>Journal of Pharmaceutical Sciences</i> , 2006 , 95, 1666-76	9.9	23
78	Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. <i>Pain</i> , 2006 , 120, 267-275	8	65
77	Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: application to a pharmacokinetic study in a methadone maintained subject. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 559-67	3.2	14
76	Fluctuations in (R,S)-methadone pharmacokinetics and response among long-term methadone maintenance patients. <i>Addiction Biology</i> , 2006 , 11, 170-4	4.6	5
75	Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 326-35	3.8	14
74	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 570-84	3.8	58
73	Blood-brain equilibration kinetics of levo-alpha-acetyl-methadol using a chronically instrumented sheep preparation. <i>British Journal of Pharmacology</i> , 2006 , 147, 209-17	8.6	3
72	ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 682-90	6.1	124
71	Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 832, 114-20	3.2	16
70	Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 843, 302-9	3.2	11

69	Switching between methadone and morphine for maintenance treatment of opioid dependence: impact on pain sensitivity and mood status. <i>American Journal on Addictions</i> , 2006 , 15, 311-5	3.7	14
68	Characterisation of the in vitro modulation of splenocyte proliferation by non-4,5-epoxymorphinan opioids. <i>International Immunopharmacology</i> , 2005 , 5, 1713-22	5.8	5
67	Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 404-13	3.8	19
66	CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. <i>Xenobiotica</i> , 2004 , 34, 875-87	2	14
65	Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 742-55	3.8	63
64	Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 536-41	3.8	15
63	Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 609-17	3.8	35
62	Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. <i>Addiction</i> , 2004 , 99, 940-5	4.6	58
61	Relationship between 4,5-epoxymorphinan structure and in vitro modulation of cell proliferation. <i>European Journal of Pharmacology</i> , 2004 , 494, 251-62	5.3	7
60	Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 456-63	3.8	6
59	Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 230-8	6.1	22
58	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 287-97	3.8	100
57	Evaluation of levo-alpha-acetylmethadol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. <i>Drug and Alcohol Dependence</i> , 2004 , 76, 63-72	4.9	23
56	In vitro opioid induced proliferation of peripheral blood immune cells correlates with in vivo cold pressor pain tolerance in humans: a biological marker of pain tolerance. <i>Pain</i> , 2004 , 110, 751-755	8	13
55	(S)-(+)-methadone is more immunosuppressive than the potent analgesic (R)-(-)-methadone. <i>International Immunopharmacology</i> , 2004 , 4, 1525-30	5.8	11
54	Changes in Methadone Concentration, Opioid Effects, and Opioid Withdrawal During Induction Onto Maintenance Treatment. <i>Addictive Disorders and Their Treatment</i> , 2004 , 3, 122-128	0.5	
53	Inside the isomers: the tale of chiral switches. <i>Australian Prescriber</i> , 2004 , 27, 47-49	1.4	24
52	Quantification of the O- and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 785, 81-8	3.2	18

51	Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. <i>Drug and Alcohol Dependence</i> , 2003 , 72, 85-94	4.9	40
50	A phase I study of the GM-CSF antagonist E21R. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 171-8,5	8.5	8
49	Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 71, 131-40	6.1	32
48	In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. <i>Addiction Biology</i> , 2002 , 7, 219-25	4.6	39
47	Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 217-27	6.1	72
46	Hyperalgesic responses in methadone maintenance patients. <i>Pain</i> , 2001 , 90, 91-6	8	215
45	Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. <i>Pain</i> , 2001 , 93, 155-163	8	120
44	The relationship between mood state and plasma methadone concentration in maintenance patients. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 78-84	1.7	54
43	Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 427-40	3.8	89
42	Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 465-71	3.8	53
41	Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. <i>British Journal of Clinical Pharmacology</i> , 1999 , 47, 403-12	3.8	135
40	Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 65, 685-94	6.1	103
39	Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1998 , 25, 266-70	3	22
38	Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine. <i>Journal of Pain and Symptom Management</i> , 1998 , 16, 112-20	4.8	25
37	The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat. <i>Pain</i> , 1997 , 71, 199-205	8	28
36	Concentration-effect relationships of morphine and morphine-6 beta-glucuronide in the rat. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1997 , 24, 359-64	3	18
35	Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. <i>Journal of Pain and Symptom Management</i> , 1997 , 14, 157-67	4.8	93
34	Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. <i>Journal of Pain and Symptom Management</i> , 1996 , 12, 182-9	4.8	143

33	The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 295-307	6.1	99
32	Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. <i>British Journal of Clinical Pharmacology</i> , 1996 , 41, 175-9	3.8	13
31	Renal transport of drugs: specificity and molecular mechanisms. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996 , 23, 986-9	3	33
30	The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. <i>Drug Metabolism Reviews</i> , 1996 , 28, 345-472	7	179
29	Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin. <i>Pharmaceutical Research</i> , 1995 , 12, 149-54	4.5	22
28	Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine. <i>Clinical Pharmacokinetics</i> , 1993 , 24, 413-20	6.2	36
27	Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes. <i>Biochemical Pharmacology</i> , 1993 , 45, 833-9	6	39
26	Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 51, 379-87	6.1	48
25	Mu receptor binding of some commonly used opioids and their metabolites. <i>Life Sciences</i> , 1991 , 48, 2165-71	6.1	185
24	Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. <i>Clinical Pharmacokinetics</i> , 1991 , 21, 394-9	6.2	25
23	Codeine O-demethylation: rat strain differences and the effects of inhibitors. <i>Biochemical Pharmacology</i> , 1991 , 41, 757-62	6	39
22	The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. <i>Biopharmaceutics and Drug Disposition</i> , 1990 , 11, 507-18	1.7	41
21	Determination of endogenous concentrations of N1-methylnicotinamide in human plasma and urine by high-performance liquid chromatography. <i>Analytical Biochemistry</i> , 1990 , 187, 160-5	3.1	18
20	Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. <i>Life Sciences</i> , 1990 , 46, 1067-74	6.8	52
19	Direct determination of codeine-6-glucuronide in plasma and urine using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. <i>Biomedical Applications</i> , 1989 , 493, 313-24		15
18	Simultaneous determination of codeine, norcodeine and morphine in biological fluids by high-performance liquid chromatography with fluorescence detection. <i>Biomedical Applications</i> , 1989 , 491, 367-78		32
17	Sensitive high-performance liquid chromatographic assay for determination of amiloride in biologic fluids using an ion-pair extraction method. <i>Therapeutic Drug Monitoring</i> , 1988 , 10, 463-8	3.2	10
16	The absorption and disposition of enoxacin in healthy subjects. <i>Journal of Clinical Pharmacology</i> , 1988 , 28, 707-13	2.9	12

15	New insights into the renal secretion of drugs. <i>Trends in Pharmacological Sciences</i> , 1987 , 8, 354-357	13.2	23
14	Pharmacokinetic interactions of cimetidine 1987. <i>Clinical Pharmacokinetics</i> , 1987 , 12, 321-66	6.2	159
13	Effect of cimetidine on renal and hepatic drug elimination: studies with triamterene. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 40, 400-7	6.1	48
12	Prescribing for the patient with renal disease. <i>Medical Journal of Australia</i> , 1986 , 145, 210-5	4	1
11	Drug disposition and dosing in hepatic disease. <i>Medical Journal of Australia</i> , 1986 , 145, 284-6, 289	4	2
10	Effect of variations in urine pH and flow rate on cimetidine renal disposition in man. <i>Biopharmaceutics and Drug Disposition</i> , 1985 , 6, 345-9	1.7	3
9	Metronidazole pharmacokinetics in patients with acute renal failure. <i>Journal of Antimicrobial Chemotherapy</i> , 1984 , 13, 183-9	5.1	17
8	Clinical pharmacokinetics of cimetidine. <i>Clinical Pharmacokinetics</i> , 1983 , 8, 463-95	6.2	117
7	Elimination of amphotericin B in impaired renal function. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 34, 248-53	6.1	28
6	Drug interactions with cimetidine. <i>Clinical Pharmacokinetics</i> , 1982 , 7, 23-41	6.2	218
5	Application of stable labelled drugs in clinical pharmacokinetic investigations. <i>Clinical Pharmacokinetics</i> , 1982 , 7, 490-507	6.2	53
4	Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 31, 501-8	6.1	6
3	Cimetidine plasma concentration-response relationships. <i>Clinical Pharmacology and Therapeutics</i> , 1981 , 29, 744-8	6.1	46
2	Rectal administration of metronidazole provides therapeutic plasma levels in postoperative patients. <i>New England Journal of Medicine</i> , 1981 , 305, 1569-70	59.2	35
1	Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. <i>Clinical Pharmacokinetics</i> , 1980 , 5, 84-94	6.2	70